Boehringer Ingelheim is funding a new initiative to tackle stroke in Europe, a leading cause of disability and death. Together with the European Stroke Organisation, it aims to have 1500 new stroke-ready centres by 2019.
Cardiovascular diseases are now the #1 cause of death all over the world, killing an estimated 17.5 million people according to the WHO. Of these, acute ischemic stroke is a particular challenge for health authorities, as patients need to be treated in very short timeframes.
With a strong cardiac program (which includes its blockbuster anti-coagulant), Boehringer Ingelheim (Germany) has been launching parallel initiatives to improve these numbers. An example is its previous collaboration with the European Society of Cardiology (ESC) to award €400k grants for research in cardiovascular diseases.
Now, Boehringer Ingelheim is joining the European Stroke Organisation (ESO) to improve the care of stroke patients. Named ‘Angels Initiative‘, this new program wants to create a community of at least 1,500 centres and hospitals specialized in stroke treatment.